Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

The limelight of adipose-derived stem cells in the landscape of neural tissue engineering for peripheral nerve injury.

QingNing S., Mohd Ismail ZI., Ab Patar MNA., Mat Lazim N., Hadie SNH., Mohd Noor NF.

Narrative Review, published in Tissue Cell (2024) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Tissue Cell (2024)
Country
Scotland
Reported sample size
—
Source database
PubMed
PMID
39293138
DOI
10.1016/j.tice.2024.102556
Citations
2

Abstract (original English)

Background and aims Challenges in treating peripheral nerve injury include prolonged repair time and insufficient functional recovery. Stem cell therapy coupled with neural tissue engineering has been shown to induce nerve regeneration following peripheral nerve injury. Among these stem cells, adipose-derived stem cells (ADSCs) are preferred due to their accessibility, expansion, multidirectional differentiation, and production of essential nutrient factors for nerve growth. In recent years, ADSC-laden nerve guide conduit has been utilized to enhance the therapeutic effects of tissue-engineered nerve grafts. This review explores existing research that recognizes the roles played by ADSCs in inducing peripheral nerve regeneration following injury and summarizes the different methods of application of ADSC-laden nerve conduit in neural tissue engineering.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Peripheral Nerve InjuriesTissue EngineeringHumansAnimalsAdipose TissueNerve RegenerationStem CellsStem Cell TransplantationCell Differentiation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.